Introduction: Laparoendoscopic single-site (LESS) technique is a less invasive approach for radical cystectomy (RC), which is promising in reducing the incisional morbidity and improving the cosmesis of laparoscopic surgery. This study aimed to investigate the clinical and oncological outcomes for patients with malignant urinary bladder tumors that underwent the transurethral-assisted transumbilical LESS-RC. Methods: From December 2014 to June 2017, 47 patients underwent LESS-RC combined with unilateral or bilateral cutaneous ureterostomy were enrolled in this study. The urethra was used as a potential approach without additional incision, which could allow for trocar insertion through natural orifices. Assessments were also conducted on preoperative, perioperative, postoperative, pathologic, and functional outcome data. Results: Mean patient age was 73 years. Mean body mass index was 24.0 kg/m2. Median operating time and estimated blood loss measure 217 min and 178 mL, respectively. Four patients were diagnosed with positive lymph nodes. Two patients had positive surgical margins. No major perioperative complications occurred. Median postoperative follow-up time was 20.1 months. Two patients died due to their progressive disease. Conclusion: LESS can serve as a feasible and effective surgical procedure for RC to treat bladder cancer. With increasing experience and improvements, LESS-RC is promising to be a relatively acceptable alternative for minimally invasive surgery in some specific patients (with generally poor conditions that cannot be tolerated for a long time surgery, short life expectancy, advanced cancer, or associated with intestinal disease).

Keywords:
Bladder cancer, Laparoendoscopic single-site surgery, Transurethral-assisted
1.
Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012.
CA Cancer J Clin
. 2012 Jan-Feb;62(1):10–29.
2.
Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients.
J Clin Oncol
. 2001 Feb;19(3):666–75.
3.
Stenzl A, Cowan NC, De Santis M, Kuczyk MA, Merseburger AS, Ribal MJ, et al.; European Association of Urology (EAU). Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines.
Eur Urol
. 2011 Jun;59(6):1009–18.
4.
Nagele U, Anastasiadis AG, Merseburger AS, Corvin S, Hennenlotter J, Adam M, et al. The rationale for radical cystectomy as primary therapy for T4 bladder cancer.
World J Urol
. 2007 Aug;25(4):401–5.
5.
Novara G, De Marco V, Aragona M, Boscolo-Berto R, Cavalleri S, Artibani W, et al. Complications and mortality after radical cystectomy for bladder transitional cell cancer.
J Urol
. 2009 Sep;182(3):914–21.
6.
Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate.
J Urol
. 2010 Sep;184(3):990–4.
7.
Shabsigh A, Korets R, Vora KC, Brooks CM, Cronin AM, Savage C, et al. Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology.
Eur Urol
. 2009 Jan;55(1):164–74.
8.
Stimson CJ, Chang SS, Barocas DA, -Humphrey JE, Patel SG, Clark PE, et al. -Early and late perioperative outcomes following radical cystectomy: 90-day readmissions, morbidity and mortality in a contemporary series. J Urol. 2010 Oct;184(4):1296–300.
9.
Skjold Kingo P, Palmfeldt J, Nørregaard R, Borre M, Jensen JB. Perioperative Systemic Inflammatory Response following -Robot-Assisted Laparoscopic Cystectomy vs. Open Mini-Laparotomy Cystectomy: A Prospective Study.
Urol Int
. 2017;99(4):436–45.
10.
Canes D, Desai MM, Aron M, Haber GP, Goel RK, Stein RJ, et al. Transumbilical single-port surgery: evolution and current status.
Eur Urol
. 2008 Nov;54(5):1020–9.
11.
Kaouk JH, Autorino R, Kim FJ, Han DH, Lee SW, Yinghao S, et al. Laparoendoscopic single-site surgery in urology: worldwide multi-institutional analysis of 1076 cases.
Eur Urol
. 2011 Nov;60(5):998–1005.
12.
Babjuk M, Burger M, Zigeuner R, Shariat SF, van Rhijn BW, Compérat E, et al.; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013.
Eur Urol
. 2013 Oct;64(4):639–53.
13.
Tsurusaki T, Takehara K. [Extraperitoneal bilateral tubeless cutaneous ureterostomy with umbilical stoma].
Hinyokika Kiyo
. 2007 Nov;53(11):789–93.
14.
Rodríguez AR, Lockhart A, King J, Wiegand L, Carrion R, Ordorica R, et al. Cutaneous ureterostomy technique for adults and effects of ureteral stenting: an alternative to the ileal conduit.
J Urol
. 2011 Nov;186(5):1939–43.
15.
Kaouk JH, Goel RK, White MA, White WM, Autorino R, Haber GP, et al. Laparoendoscopic single-site radical cystectomy and pelvic lymph node dissection: initial experience and 2-year follow-up.
Urology
. 2010 Oct;76(4):857–61.
16.
Ma LL, Bi H, Hou XF, Huang Y, Wang GL, Zhao L, et al. Laparoendoscopic single-site radical cystectomy and urinary diversion: initial experience in China using a homemade single-port device. J Endourol. 2012 Apr;26(4):355–9.
17.
Zhu C, Su J, Yuan L, Zhang Y, Lu ZJ, Su Y, et al. Transurethral assistant transumbilical laparoendoscopic single-site radical prostatectomy.
Asian J Androl
. 2017 Jul-Aug;19(4):473–6.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.